Cite
Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?
MLA
Miolo G, et al. “Weekly Paclitaxel in Heavily Pretreated Ovarian Cancer Patients: Does This Treatment Still Provide Further Advantages?” Archives of Gynecology & Obstetrics, vol. 285, no. 2, Feb. 2012, pp. 499–503. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=104399113&authtype=sso&custid=ns315887.
APA
Miolo G, Bidoli E, Lombardi D, Santeufemia DA, Capobianco G, Dessole F, Scalone S, Spazzapan S, Sorio R, Tabaro G, & Veronesi A. (2012). Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages? Archives of Gynecology & Obstetrics, 285(2), 499–503.
Chicago
Miolo G, Bidoli E, Lombardi D, Santeufemia DA, Capobianco G, Dessole F, Scalone S, et al. 2012. “Weekly Paclitaxel in Heavily Pretreated Ovarian Cancer Patients: Does This Treatment Still Provide Further Advantages?” Archives of Gynecology & Obstetrics 285 (2): 499–503. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=104399113&authtype=sso&custid=ns315887.